On 18 December 2024, Australia’s Pharmaceutical Benefits Scheme (PBS) published its agenda for the May 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting.
The May 2025 agenda lists 8 biologics for consideration, 3 of which are listed for new PBS additions:
New listing applications
- UCB’s Bimzelx® (bimekizumab) moderate to severe hidradenitis suppurativa
- AstraZeneca’s Imjudo® (durvalumab) in combination with tremelimumab for the first line treatment of patients with advanced (unresectable) Stage B Barcelona clinic liver cancer or Stage C hepatocellular carcinoma.
- Accelagen’s Briumvi® (ublituximab) for relapsing-remitting multiple sclerosis
Amendment applications
- GSK’s Jemperli® (dostarlimab) for use in combination with platinum-containing chemotherapy for the treatment of primary advanced or first recurrent mismatch repair proficient endometrial cancer
- Janssen’s Tremfya® (guselkumab) for severe chronic plaque psoriasis
- Novartis’ Xolair® (omalizumab) for CRSwNP
- Novartis’ Lucentis® (ranibizumab) for proliferative diabetic retinopathy
- AstraZeneca’s Enhertu® (trastuzumab deruxtecan) for gastric or gastroesophageal junction cancer
In November 2024, PBAC previously published its agenda for the March 2025 meeting, which will consider 23 monoclonal antibodies, including four biosimilars.